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Summary
Spinal muscular atrophy (SMA) is a relatively common
autosomal recessive neuromuscular disorder. We have
identified de novo rearrangements in 7 (∼2%) index
patients from 340 informative SMA families. In each,
the rearrangements resulted in the absence of the
telomeric copy of the survival motor neuron (SMN) gene
(telSMN), in two cases accompanied by the loss of the
neuronal apoptosis–inhibitory protein gene . Haplotype
analysis revealed unequal recombination in four cases,
with loss of markers Ag1-CA and C212, which are near
the 5′ ends of the SMN genes. In one case, an
interchromosomal rearrangement involving both the
SMN genes and a regrouping of Ag1-CA and C212
alleles must have occurred, suggesting either
interchromosomal gene conversion or double
recombination. In two cases, no such rearrangementwas
observed, but loss of telSMN plus Ag1-CA and C212
alleles in one case suggested intrachromosomal deletion
or gene conversion. In six of the seven cases, the de novo
rearrangement had occurred during paternal meiosis.
Direct detection of de novo SMA mutations by
molecular genetic means has allowed us to estimate for
the first time the mutation rate for a recessive disorder
in humans. The sex-averaged rate of , arrived41.1# 10
at in a proband-based approach, compares well with the
rate of expected under a mutation-selection40.9# 10
equilibrium for SMA. These findings have important
implications for genetic counseling and prenatal
diagnosis in that they emphasize the relevance of indirect
genotype analysis in combination with direct SMN-gene
deletion testing in SMA families.
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Introduction
Proximal spinal muscular atrophy (SMA) is an auto-
somal recessive neurodegenerative disorder leading to
weakness and atrophy of the voluntary muscles. Because
of the large phenotypic variability of SMA, patients have
been classified into three types (I–III), depending on
achieved motor milestones and age at onset (Interna-
tional SMA Consortium 1992; Zerres and Rudnik-
Scho¨neborn 1995). Five years after the gene for all three
SMA types had been mapped to 5q11.2-q13.3 (Brzus-
towicz et al. 1990; Gilliam et al. 1990; Melki et al.
1990a, 1990b), two candidate genes were reported: the
survival motor neuron (SMN) gene (Lefebvre et al. 1995)
and the neuronal apoptosis–inhibitory protein (NAIP)
gene (Roy et al. 1995).
The SMN gene is present in two highly homologous
copies—a telomeric (telSMN) copy and a centromeric
(cenSMN) copy—which differ only by a small number
of nucleotide substitutions (Lefebvre et al. 1995; Bu¨rglen
et al. 1996; Brahe et al. 1996; Hahnen and Wirth 1996).
Irrespective of clinical severity, 190% of SMA patients
lack exon 7, or both exon 7 and exon 8, of telSMN
(Cobben et al. 1995; Hahnen et al. 1995; Lefebvre et
al. 1995; Rodrigues et al. 1995). In patients with ho-
mozygous absence of telSMN exon 7 only, the remaining
exon 8 was consistently shown to be part of a hybrid
SMN gene, providing evidence for unequal recombi-
nation or gene conversion as the major molecular mech-
anisms underlying the disease (Hahnen et al. 1996; van
der Steege et al. 1996; DiDonato et al. 1997). Although
occasional homozygous deletions of telSMN in unaf-
fected individuals may argue against a causative role of
telSMN in the pathology of SMA (Cobben et al. 1995;
Hahnen et al. 1995;Wang et al. 1996), several intragenic
mutations identified in nondeleted SMA patients support
the view that telSMN is an SMA-determining gene (Bus-
saglia et al. 1995; Lefebvre et al. 1995; Brahe et al. 1996;
Parsons et al. 1996; Hahnen et al. 1997; Talbot et al.
1997).
The NAIP gene is present in one functional copy and
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several truncated pseudogenes (Roy et al. 1995). Ho-
mozygous deletion of exons 5 and 6 of the NAIP gene
has been observed in ∼50% of type I SMA patients and
in !20% of type II and type III SMA patients but also
in 1%–2% of unaffected individuals (Cobben et al.
1995; Hahnen et al. 1995; Roy et al. 1995).
The SMA critical region consists of a duplicated and
inverted element of ∼500 kb, comprising several mor-
phic marker loci in addition to the SMN, NAIP, and
other genes and pseudogenes (Burghes et al. 1994;
DiDonato et al. 1994; Melki et al. 1994; Lefebvre et al.
1995; Roy et al. 1995; Bu¨rglen et al. 1997). Two poly-
morphic multicopy markers, Ag1-CA (C272) and C212,
are localized close to the 5′ ends of the SMN genes
(DiDonato et al. 1994; Melki et al. 1994; Bu¨rglen et al.
1996). The copy number of these markers has been
shown to be reduced in patients with severe SMA
(DiDonato et al. 1994; Melki et al. 1994; Wirth et al.
1995a).
A small number of de novo rearrangements involving
telSMN, Ag1-CA, and C212 has been reported. In most
cases, the patients exhibited loss of telSMN and of Ag1-
CA and C212 alleles when compared with an unaffected
sib haploidentical for single-copy markers flanking the
SMA critical region (Melki et al. 1994; Capon et al.
1995; Rodrigues et al. 1995; Wirth et al. 1995a; Raclin
et al. 1997).
The present study is the first to report a larger number
of de novo rearrangements in SMA patients, thus allow-
ing inference as to the underlying mutational mecha-
nisms, determination of the parental origin of mutation,
assessment of the implications for prenatal diagnosis and
genetic counseling, and estimation of the mutation rate,
m, for SMA.
Patients and Methods
Family Ascertainment
All patients fulfilled the diagnostic criteria defined by
the International SMA Consortium (1992; also see Zer-
res and Rudnik-Scho¨neborn 1995). Clinical diagnosis
was confirmed by homozygous absence of at least exon
7 of telSMN. On this basis, we have included family A
even though the patient in that family presented with
features excluding SMA, such as distal joint contractures
and cerebral atrophy. De novo rearrangements in fam-
ilies F and G have been described elsewhere (Wirth et
al. 1995a). Informed consent was obtained from all sub-
jects prior to sampling.
The following criteria were defined for the inclusion
of an SMA family in the present study: (1) the index
patient, both parents, and at least one further sib had
to be available for DNA analysis; (2) SMA patients had
to be homozygous for the absence of at least exon 7 of
telSMN; and (3) marker analysis including Ag1-CA and
C212 had to be informative, so as to allow unambiguous
reconstruction of haplotypes.
Molecular Analysis
Molecular analysis of SMA candidate genes SMN (Le-
febvre et al. 1995) and NAIP (Roy et al. 1995) was
performed as described by Hahnen et al. (1995); that of
markers Ag1-CA (D5S1556) (DiDonato et al. 1994) and
C212 (D5F149S1/S2) (Melki et al. 1994) was performed
as described by Wirth et al. (1995a); and that of flanking
single-copy markers (listed from centromere to telomere)
EF13/14 (D5S680), JK348 (D5S435), AFM265wf5
(D5S629), A31 (D5S823), 2AE9.1 (D5S557),
AFM281yh9 (D5S637), MITI105 (D5S351), RB110/
111 (5′MAP1B), and RB104/106 (3′MAP1B) was per-
formed as described by Wirth et al. (1994, 1995b). Hap-
lotypes for multicopy markers Ag1-CA and C212 were
reconstructed as described by Wirth et al. (1995a).
Estimation of m
When family history regarding the presence or absence
of disease is not taken into consideration, the probability
of a healthy couple having a child with an autosomal
recessive disorder is approximately
2( ) ( )1/4# 2q 1 q  2# 1/2# m# 2q 1 q[ ]
2 2 2 2( ) ( )# 1 q  m # 1 q , (1)[ ]
in which q is the population frequency of the disease
allele(s). The three terms in formula (1) correspond to
none, one, or two of the mating partners being heter-
ozygous for the disease allele, respectively. Thus, the pro-
portion of cases in which an affected proband carries a
new mutation, r, equals the ratio of the second term over
the total sum. Since m2 is usually small and ap-1 q
proximates unity, this ratio can be simplified to
( )r  2m/ q 2m . (2)
m can thus be estimated from a given estimate, r*, of r,
via
∗ ∗ ∗( )m  r q 2 2r , (3)
if q is known. The quantity m* is a maximum-likelihood
estimate of m even if r is estimated from a sample in
which some families have two or more affected children
(which families will then almost always carry two in-
herited lesions). This is because the conditional proba-
bility of any realistic number of affected sibs, given the
proband, is virtually independent of m if m is small. It
has to be ensured, however, that only one patient (i.e.,
the proband) is counted in multiplex families when the
denominator of r* is determined.
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Results
Identification of De Novo Rearrangements
The SMN gene and the polymorphic multicopy mark-
ers Ag1-CA and C212 were analyzed, for various sci-
entific and clinical reasons, in 1400 SMA families. From
351 families, DNA of the parents and at least two chil-
dren (including the SMN-deleted index patient) was
available. Of these 351, a total of 340 SMA families
(211 type I, 78 type II, and 51 type III) fulfilled the
above-mentioned criteria (see Patients andMethods) and
were included in the present study. In seven of these
families, the only affected individual was found to carry
a de novo rearrangement involving telSMN. Five of the
patients were type I SMA, one was type II, and one was
type III. Pedigrees and reconstructed haplotypes are pre-
sented in figure 1; and themajor findings are summarized
in table 1.
All seven patients showed homozygous lack of
telSMN exons 7 and 8; only two patients were also
homozygous for deletion of NAIP exons 5 and 6. Crucial
evidence for a de novo rearrangement was provided by
haplotype analysis with polymorphic multicopymarkers
Ag1-CA and C212. In six cases (families A–F), various
alleles of these markers were involved in the de novo
rearrangement.
In families A, B, and F, the patient showed homozy-
gous deletion of telSMN exons 7 and 8, as well as loss
of one Ag1-CA and one C212 allele, compared with the
paternal haplotype. In families A and B, the patients
(both type I SMA) were also lacking NAIP exons 5 and
6. In family D, the patient exhibited a large scale-deletion
comprising both paternal Ag1-CA and C212 alleles, in
addition to telSMN. In family C, a loss of only one Ag1-
CA allele and the absence of telSMN were identified in
the patient. In family G, the patient did not display any
rearrangement involving Ag1-CA and C212 but lacked
telSMN, when compared with his haploidentical
brother. In family E, the patient showed a rearrangement
that resulted not in a loss but in a regrouping of paternal
Ag1-CA and C212 alleles, in addition to the loss of
telSMN. In the case of Ag1-CA, allele 114 was replaced
by allele 104; in the case of C212, allele 22 was replaced
by allele 29. Since the two healthy sibs of this patient
inherited the same maternal chromosome as the patient
but had different paternal chromosomes, the father did
not seem to be a carrier of SMA.
Mutational Mechanisms of De Novo Rearrangement
While haplotype analysis using markers Ag1-CA and
C212, together with SMN deletion testing, allowed the
identification of de novo rearrangements, only the in-
clusion of additional single-copy flanking markers en-
abled us to disclose the most likely underlying
mechanisms.
Haplotype analysis with flanking markers revealed
unequal crossing-over between parental chromosomes in
four cases (families A–D), resulting in the absence of
telSMN, of various marker alleles, and, in two cases, of
NAIP. In the remaining three cases (families E–G), no
recombination involving markers flanking the SMA re-
gion could be observed. Haplotype analysis in family F
therefore suggests intrachromosomal deletion compris-
ing AG1-CA/C212 alleles and telSMN, whereas in fam-
ily G we cannot distinguish between intrachromosomal
deletion and gene conversion. In family E, double re-
combination or interchromosomal gene conversion dur-
ing paternal meiosis resulted in the interchromosomal
rearrangement of Ag1-CA and C212 alleles and the loss
of telSMN.
Parental Origin of De Novo Rearrangements
The paternal origin of the de novo rearrangements
could be determined in six cases (A–F). In family G, none
of the markers was involved in the rearrangement, so
the parental origin could not be identified. The average
paternal age at birth of the index patient was 27.5 years
(range 23–34 years), which compares well to the average
in the general population.
Interestingly, in all four cases with unequal crossing-
over, the paternal haplotypes show an unbalanced copy
number, at least for Ag1-CA: in families A, B, and D,
the paternal chromosomes carry one and two Ag1-CA
alleles (genotype 1,2); in family C, the paternal chro-
mosomes carry 1 and 3 alleles (genotype 1,3); and, in
family F, in which an intrachromosomal deletion is the
most probable mutational mechanism, marker C212
carries two and three copies on the paternal chromo-
somes (genotype 2,3).
Estimation of m in SMA
In 7 (2%) of 340 SMA families, the index patient was
found to carry a de novo rearrangement. Since it is
known that mutations other than homozygous absence
of telSMN are rare in SMA patients, this proportion
represents a good estimate of the parameter r, as defined
in formula (2). If it is assumed that r  7/340  .021
and that , then formula (3) yields an estimateq  1/100
of for SMA. As can be inferred from4m  1.1# 10
figure 2, this is close to the m expected from mutation-
selection equilibrium, for a broad2m  (1 f )# q ,
range of fitness values, f. Adopting the upper (.038) and
lower (.012) 95% confidence limits for the parameter r
results in confidence limits for m are and41.9# 10
, respectively. For these estimates to concur56.1# 10
with their equilibrium expectation, however, q would
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Figure 1 Pedigrees of SMA families with de novo rearrangements. Haplotype analysis of markers Ag1-CA and C212 and of informative
single-copy markers is included. In pedigree G, the most likely haplotype is shown.
have to be either two times larger or two times smaller
than that suggested by the 1/10,000 observed incidence
of SMA (see fig. 2 ).
Since six of the seven de novo mutations were une-
quivocally of paternal origin, adoption of a sex-averaged
m for SMA may seem questionable. Thus, if sex-specific
m values were allowed in formulas (1), (2), and (3), the
estimate for males would approximate twice the sex-
averaged figure whereas that for females would be es-
timated as zero. Breakdown of the analysis by disease
type, on the other hand, is problematic for a recessive
disease such as SMA, since estimation of m, either by
our direct approach or indirectly, when mutation-selec-
tion disequilibrium is assumed, would depend on q. For
SMA, however, this entity is not yet well defined. A
particular allele causing a particular disease type in the
homozygous state may well cause a different type when
it occurs in the compound-heterozygous state with an-
other, say, milder allele. Nevertheless, since r for SMA
I families (5/211) is literally identical to that noted for
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Table 1
Characterization of Seven De Novo Rearrangements in Patients with SMA
Family
SMA
Type
telSMN,
exons 7 and 8
NAIP,
exons 5 and 6 Ag1-CA and C212 Recombination?
Parent of
Origin
Paternal
Age at
Birth of
Patient
(years)
Mutational
Mechanism
A I Deleted Deleted Loss of one Ag1-CA
copy and one C212
copy
Yes Father 24 Unequal
recombination
B I Deleted Deleted Loss of one Ag1-CA
copy and one C212
copy
Yes Father 25 Unequal
recombination
C I Deleted Present Loss of one Ag1-CA
copy
Yes Father 34 Unequal
recombination
D I Deleted Present Loss of two Ag1-CA
copies and two
C212 copies
Yes Father 27 Unequal
recombination
E I Deleted Present
Regrouping of one
Ag1-CA and one
C212 copy
Yes Father 30 Interchromosomal
gene conversion
or double
recombination
F III Deleted Present Loss of one Ag1-CA
copy and one C212
copy
No Father 30 Intrachromosomal
deletion
G II Deleted Present No marker
rearrangement
No Unknown 23 Gene conversion
or intrachro-
mosomal
deletion
Figure 2 Relationship between m and q, for SMA. The upper
and lower continuous curves demarcate the 95% confidence intervals
for the estimate of m emerging, at a given value of q, from the obser-
vation that 7/340 SMA probands carry a de novo mutation in the
heterozygous state. The central continuous curved line depicts themax-
imum-likelihood estimate of m. Broken lines represent the mutation-
selection equilibrium ensuing for various f for SMA.
all SMA types combined (7/340), there is as yet no ev-
idence for a significant difference in the rate at which
mutations associated with either SMA type are
generated.
Discussion
Identification of De Novo Rearrangements
Although the identification of de novo mutations for
an autosomal dominant inherited disorder is straight-
forward via sporadic cases, there is no way in which
recessive inherited disorders can be used to determine,
on the basis of family history, which patients carry a de
novo mutation. This is the first report of a sufficiently
large number of SMA families in which the parents and
at least two children have been analyzed for both the
multicopy markers Ag1-CA and C212 and the SMN
gene. Analysis of at least these four individuals is a pre-
requisite for identification of de novo mutations in a
given family. If no sibs of the index patient are available,
the haplotype analysis of grandparents may help to dis-
close de novo mutations. The few de novo mutations
described so far have not been found in the course of
systematic studies of a large number of SMA families,
and, therefore, the ensuing relative mutation frequencies
are not comparable (Melki et al. 1994; Capon et al.
1995; Rodrigues et al. 1995; Wirth et al. 1995a; Raclin
et al. 1997).
We found seven de novo rearrangements comprising
telSMN and the immediately surrounding region in 340
SMA families. Two haplotype constellations were help-
ful in revealing de novo rearrangements: (1) familieswith
haploidentical affected and unaffected sibs and (2) fam-
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ilies with a crossing-over between markers closely flank-
ing the SMA region.
In a previous study, we observed that ∼15% of type
I SMA and ∼6% of type II SMA patients had inherited
a large-scale deletion from one parent, which implies
that, in these families, one SMA chromosome was lack-
ing Ag1-CA and C212 alleles (Wirth et al. 1995a). Some
authors have erroneously mistaken such lesions for de
novo deletions (Melki et al. 1994; Capon et al. 1996).
McAndrew et al. (1997) recently published a quan-
titative analysis of the telomeric and centromeric SMN
genes of SMA patients, SMA carriers, and controls. Al-
though their method might be useful for identification
of de novo mutations in many cases, the authors them-
selves reported a carrier (76 individuals were tested)who
had two affected children with deletions but who nev-
ertheless carried two telSMN copies. Since two inde-
pendent de novo mutations were deemed unlikely, the
most parsimonious explanation for this finding was that
the two telSMN copies were on the same chromosome.
This phenomenon has also been observed in 3% con-
trols. Therefore, quantitative SMN-gene analysis cannot
replace a qualitative analysis using multicopy markers
and the SMN gene. However, quantitative analysismight
help to determine the parental origin of de novo mu-
tations that involve the SMN gene only.
Mutational Mechanisms of De Novo Rearrangement in
SMA Patients
Three mechanisms seem to play a crucial role in the
occurrence of de novo mutations in SMA: (1) unequal
crossing-over between homologous chromosomes, (2)
intrachromosomal deletion, and (3) gene conversion.Re-
cently, the same mechanisms have been suggested as the
mechanism for the generation of hybrid SMN genes
(Hahnen et al. 1996).
Because of its duplicated structure, including SMN
and NAIP homologues, the SMA region seems to be
prone to unequal rearrangement or gene conversion.
Findings in a number of other genes indeed suggest that
repetitive regions are susceptible to these types of lesions
(for review, see Cooper et al. 1995).
Interestingly, unequal crossing-over involving the
SMA region seems to be associated with an unbalanced
genomic structure, as reflected by the copy number of
Ag1-CA on homologous chromosomes (families A–D).
In view of the localization of Ag1-CA alleles within the
promoter region of the SMN genes, this marker might
roughly reflect the number of repeated elements includ-
ing the SMN genes. Thus, differences in Ag1-CA copy
number on both chromosomes could represent differ-
ences in physical structure that might predispose to de
novo rearrangements.
In those families in which the de novo rearrangement
resulted in a deletion (families A–D and F), the different
number of lost marker alleles and genes suggests differ-
ent deletion sizes. It appears that unequal recombina-
tions causing larger deletions are associated with more
severe phenotypes, whereas intrachromosomal deletions
and gene conversions are associated with milder SMA.
Our data are thus consistent with a recent genotype-
phenotype study in which pulsed-field gel electrophoresis
has provided evidence that gene conversion of telSMN
into cenSMN predominates in patients with mild SMA
(Campbell et al. 1997). An increased number of cenSMN
copies was also found in a number of mild SMA cases
by quantitative analysis (Burghes 1997; McAndrew et
al. 1997). We may thus summarize that, whereas severe
SMA mutations are more likely to be deletions, mild
SMA mutations are mainly due to gene conversion.
Parental Origin
In six of seven rearrangements we were able to de-
termine the paternal origin of the de novo mutation.
Melki et al. (1994) also reported a de novo telSMN
deletion of paternal origin. However, since no flanking
markers were tested, the underlying mechanism could
not be disclosed. The de novo deletion presented by Ro-
drigues et al. (1995) resembles that in family G in that
the parental origin could not be determined. Raclin et
al. (1997) described a case in which the most likely mu-
tational mechanism was similar to that in family F
(Wirth et al. 1995a; present paper), but the mutation
that they reported was of maternal origin. This is the
only maternal de novo mutation described so far.
A bias toward a paternal origin of new mutations has
been inferred for some autosomal dominant disorders,
such as retinoblastoma, neurofibromatosis, Wilms tu-
mor, and Apert syndrome (for review, see Chandley
1989, 1991; Moloney et al. 1996). In these conditions,
de novo mutations are thought to originate mainly dur-
ing spermatogenesis, involvingmitotic replication errors,
and a paternal age effect has been documented for many
of them (for review, see Vogel and Motulsky 1996).
However, since deletion resulted from meiotic unequal
chromatid exchange in most of our cases, no paternal-
age effect was to be expected. Indeed, the average
paternal age at birth of a patient carrying a de novo
mutation was 27.5 years (range 23–34 years), which
concurs with the normal range.
The SMA region shows some similarity to chromo-
some region 17p11.2, which contains a 1.5-Mb frag-
ment flanked by repeated elements. This region is known
to undergo unequal recombination with consequent de-
letion or duplication, causing either hereditary neuro-
pathy with liability to pressure palsies or Charcot-Marie-
Tooth disease type 1A (CMT1A). For both diseases, de
novo mutations also occur mainly during spermatogen-
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esis (Palau et al. 1993; Blair et al. 1996; Pentao et al.
1997), although the recombination frequency in this par-
ticular region is higher in females than in males. Ma-
ternal de novo mutations seem to be very rare, since
only two cases have been reported so far (Blair et al.
1996; LeGuern et al. 1996). Two possible explanations
have been proposed to explain this sex difference: either
misalignment of repeated sequences is more frequent
during male meiosis, or paternally derived duplicated
chromosomes are more stable than maternal ones (Palau
et al. 1993). The proportion of de novo duplications in
CMT1A is estimated to be ∼10% (Blair et al. 1996).
Estimation of m in SMA
Our large study of de novo mutations in SMA patients
has allowed us to estimate m for SMA directly on the
basis of molecular-genetic findings. To our knowledge,
this represents the first attempt to estimate the m for an
autosomal recessive disorder in humans. The result
shows that m for SMA corresponds to that expected from
the high incidence of the disease under mutation-selec-
tion equilibrium. The incidence for recessive disorders
can be substantially influenced by factors such as fitness,
reproductive disadvantages, and genetic drift (Vogel and
Motulsky 1996). However, since our direct estimate of
fits its theoretical expectation, the data4m  1.1# 10
reported herein provide no evidence that such confound-
ing factors are seriously important in SMA.
When calculating m, we deliberately avoided breaking
down the analysis by SMA type. m values refer to changes
from “normal” to clearly defined “pathological” states,
implying that, of two identical changes, either both are
scored or neither is. At present, however, nothing is
known about the phenotypic consequences of “severe”
mutations in heterozygous combination with “mild” al-
leles. The severe allele might dominate the mild one, or
vice versa. We have shown, for example, that the most
frequent haplotype in hybrid genes (100/106 Ag1-CA
and 31/33 C212) causes a mild phenotype in the ho-
mozygous state but can lead to all three types of SMA
in heterozygotes (Hahnen et al. 1996). Even more strik-
ing was the report, by Rudnik-Scho¨neborn et al. (1996),
of two SMN-deleted sibs who had inherited the same
maternal, but different paternal, SMA chromosomes.
Whereas their father was himself suffering type III SMA
and one son presented with type I SMA, the other, elder
son was asymptomatic. In any case, since r for SMA I
families (5/211 families) is literally identical to that noted
for all SMA types combined (7/340 families), there is as
yet no evidence for a significant difference in the rate at
which mutations associated with either SMA type are
generated.
In two cases, we postulated gene conversion as being
the most likely mutational mechanism.Gene conversions
may either be confined to the SMN gene or include the
multicopy markers. In the latter case, one multicopy
marker allele will be duplicated whereas the other should
be missing, compared with the parental haplotype; mu-
tations of the former type, by contrast, can be identified
only if exons 7 and 8 are involved. This implies that a
small number of de novo gene conversions may not be
recognizable. We are aware that our estimate of m is
based on a single population frequency, q, disregarding
mutation type, but, in light of the results discussed
above, no strong effect of gene conversions and deletions
being combined in that parameter is to be expected. If
a large proportion of de novo gene conversions had been
overlooked, however, our comparatively high estimate
of m would still represent an underestimate.
Another factor that could have biased our direct es-
timate of the m is the fact that ascertainment of families
was based on informativity. However, the twomulticopy
markers together yield almost 100% informativity, and
the proportion of families in which unambiguous con-
struction of haplotypes was not feasible was low (3%).
Therefore, ascertainment bias is unlikely to represent a
serious source of error here.
Our finding of de novo mutations in 2% of index
SMA patients most likely represents a lower limit, and
the same is likely to hold for the emerging m, 1.1#
. m values of similarly high order have so far only410
been found for some dominant disorders (Vogel andMo-
tulsky 1996). However, although a dominant mutation
causing a severe phenotype is rapidly eliminated from
the population, the frequency of a recessive mutation
usually increases comparatively slowly until mutation-
selection equilibrium is reached. Therefore, despite the
correspondence noted here between the direct and in-
direct m estimates for SMA, a general prior assumption
of mutation-selection disequilibrium is not meaningful
for recessive disorders.
In cystic fibrosis (CF), the most frequent autosomal
recessive disorder, with a heterozygosity frequency of
∼4%, only two de novo mutations (White et al. 1991;
Cremonesi et al. 1996) have been described in some
30,000 CF families tested (frequency !0.01%), and the
most frequent CF mutation, DF508, is likely to be of
unique origin. It has been suggested that individuals het-
erozygous for CF are more resistant to cholera, causing
a heterozygote advantage during epidemics of cholera
(Gabriel et al. 1994). Thus, the high incidence of CF is
not a consequence of a particularly high m.
Furthermore, whereas the mutations seen in CF are
usually small (few-base-pair deletions, duplications, or
single-base-pair substitutions), mutations in SMA are
caused by complex genomic rearrangements. Mutations
caused by different mechanisms, however, can also be
assumed to occur at different frequencies.
Allelic association has been observed in SMA (Burghes
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et al. 1994; DiDonato et al. 1994; Wirth et al. 1995a),
which seems to contradict the high m. One might hy-
pothesize, however, that certain chromosomes are pre-
disposed to de novo rearrangements or that particular
marker haplotypes are associated with a mild course of
disease.
An alternative method for direct determination of the
m would have been single-sperm analysis of the SMN
gene. However, our results suggest that the diploid pa-
ternal genotype may be critical for the occurrence of de
novo mutations. Therefore, it would have been necessary
to analyze a large number of sperm donors with different
genotypes and to compare the results with each other.
Furthermore, since the accuracy of the typing of several
markers in a single sperm is questionable, it would have
been impossible to obtain reliable information as to the
mechanism underlying any mutation observed.
Implications for Prenatal Diagnosis
Most of the de novo rearrangements presented here
were identified through prenatal diagnosis in SMA fam-
ilies. We would therefore like to emphasize the impor-
tance of indirect haplotype analysis in combination with
direct SMN deletion testing, for the molecular diagnosis
of SMA. Haplotype analysis including the index patient,
the parents, and sibs, using the polymorphic multicopy
markers Ag1-CA and C212, can disclose the occurrence
of de novo rearrangements, can help to excludematernal
contamination in cases of prenatal diagnosis, and allows
one to determine the heterozygote status.
The detection of a de novo rearrangement resulting
in the loss of the telSMN gene in an SMA family indi-
cates a recurrence risk reduced from 25% to a substan-
tially lower percentage, the only risk in this situation
coming from recurrent de novo mutation or germ-line
mosaicism.
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